Drug intelligence / Profile preview

methoxyphenamine hydrochloride

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Methoxyphenamine hydrochloride is a small molecule pharmaceutical drug classified as a β-adrenergic receptor agonist. It acts primarily on β-adrenoceptors to relax bronchial smooth muscle and relieve bronchospasm, making it effective in the treatment of bronchial asthma. Its bronchodilatory effect is stronger than that of ephedrine, while its central nervous system stimulation and cardiovascular effects are weaker. After oral administration, it is rapidly absorbed from the gastrointestinal tract, metabolized in the liver, and excreted via urine. The duration of action typically lasts 3–4 hours. Methoxyphenamine hydrochloride is indicated for bronchial asthma[1][6].

Brand names: AsmetonOrthoxine
Other names: 盐酸甲氧那明2-methoxy-N,α-dimethylphenethylamine hydrochloride

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on methoxyphenamine hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methoxyphenamine hydrochloride.

Explore the full profile